Baseline and on-treatment characteristics of responding patients
| Characteristics . | All (N = 130) . | Transient response (N = 46) . | Durable response (N = 83) . | P . |
|---|---|---|---|---|
| Age, y, median (range) | 59.0 (18-78) | 60.5 (18-78) | 57.0 (19-77) | .71 |
| Sex, male, no. (%) | 80 (61.5) | 33 (71.7) | 46 (55.4) | .068 |
| Stage, III/IV (vs I/II), no. (%) | 96 (73.8) | 33 (71.7) | 62 (74.7) | .71 |
| ECOG PS preinfusion, no. (%) | .72* | |||
| 2 vs 0 to 1 | 9 (6.9) | 4 (8.7) | 5 (6.0) | |
| Extranodal involvement, no. (%) | .99 | |||
| 2 or more sites | 28 (21.5) | 10 (21.7) | 18 (21.7) | |
| Bulk (≥7.5 cm) | 30 (23.1) | 14 (30.4) | 16 (19.3) | .15 |
| COO, no. (%), n = 97 | .19 | |||
| Non-GCB (vs GCB) | 40 (41.2) | 10 (31.3) | 29 (45.3) | |
| Double/triple hit, no. (%), n = 108 | .67 | |||
| Double/triple hit (vs none) | 13 (12.0) | 6 (15.8) | 7 (10.1) | |
| Double/triple expressor (vs none) | 16 (14.8) | 5 (13.2) | 11 (15.9) | |
| Refractory to last treatment, no. (%) | 86 (66.2) | 32 (69.6) | 53 (63.9) | .51 |
| Bridging therapy, no. (%) | .83* | |||
| Systemic | 67 (51.5) | 25 (54.3) | 42 (50.6) | |
| RT | 30 (23.1) | 9 (19.6) | 20 (24.1) | |
| Combined modality | 5 (3.8) | 1 (2.2) | 4 (4.8) | |
| LDH preinfusion, no. (%), n = 104 | .041† | |||
| >ULN (vs normal) | 50 (48.1) | 20 (55.6) | 29 (43.3) | |
| >2 ULN (vs normal) | 12 (11.5) | 6 (16.7) | 6 (9.0) | |
| CRP preinfusion, median (range), n = 104 | 11.2 (0.5-235) | 22.5 (1-235) | 6.8 (0.5-160) | .003 |
| CAR-T product, no. (%) | ||||
| Axi-cel | 107 (82.3) | 39 (84.8) | 67 (80.7) | .56 |
| Tisa-cel | 23 (17.7) | 7 (15.2) | 16 (19.3) | |
| Grade ≥3 CAR-T toxicity, no. (%) | ||||
| CRS | 11 (8.5) | 6 (13.0) | 5 (6.0) | .20* |
| ICANS | 22 (16.9) | 8 (17.4) | 13 (15.7) | .80 |
| DS at 1 mo, no. (%) | ||||
| DS 1-2 | 40 (30.8) | 6 (13.0) | 34 (41.0) | <.0001† |
| DS 3 | 31 (23.8) | 10 (21.7) | 21 (25.3) | |
| DS 4 | 46 (35.4) | 17 (37.0) | 28 (33.7) | |
| DS 5 | 13 (10.0) | 13 (28.3) | 0 |
| Characteristics . | All (N = 130) . | Transient response (N = 46) . | Durable response (N = 83) . | P . |
|---|---|---|---|---|
| Age, y, median (range) | 59.0 (18-78) | 60.5 (18-78) | 57.0 (19-77) | .71 |
| Sex, male, no. (%) | 80 (61.5) | 33 (71.7) | 46 (55.4) | .068 |
| Stage, III/IV (vs I/II), no. (%) | 96 (73.8) | 33 (71.7) | 62 (74.7) | .71 |
| ECOG PS preinfusion, no. (%) | .72* | |||
| 2 vs 0 to 1 | 9 (6.9) | 4 (8.7) | 5 (6.0) | |
| Extranodal involvement, no. (%) | .99 | |||
| 2 or more sites | 28 (21.5) | 10 (21.7) | 18 (21.7) | |
| Bulk (≥7.5 cm) | 30 (23.1) | 14 (30.4) | 16 (19.3) | .15 |
| COO, no. (%), n = 97 | .19 | |||
| Non-GCB (vs GCB) | 40 (41.2) | 10 (31.3) | 29 (45.3) | |
| Double/triple hit, no. (%), n = 108 | .67 | |||
| Double/triple hit (vs none) | 13 (12.0) | 6 (15.8) | 7 (10.1) | |
| Double/triple expressor (vs none) | 16 (14.8) | 5 (13.2) | 11 (15.9) | |
| Refractory to last treatment, no. (%) | 86 (66.2) | 32 (69.6) | 53 (63.9) | .51 |
| Bridging therapy, no. (%) | .83* | |||
| Systemic | 67 (51.5) | 25 (54.3) | 42 (50.6) | |
| RT | 30 (23.1) | 9 (19.6) | 20 (24.1) | |
| Combined modality | 5 (3.8) | 1 (2.2) | 4 (4.8) | |
| LDH preinfusion, no. (%), n = 104 | .041† | |||
| >ULN (vs normal) | 50 (48.1) | 20 (55.6) | 29 (43.3) | |
| >2 ULN (vs normal) | 12 (11.5) | 6 (16.7) | 6 (9.0) | |
| CRP preinfusion, median (range), n = 104 | 11.2 (0.5-235) | 22.5 (1-235) | 6.8 (0.5-160) | .003 |
| CAR-T product, no. (%) | ||||
| Axi-cel | 107 (82.3) | 39 (84.8) | 67 (80.7) | .56 |
| Tisa-cel | 23 (17.7) | 7 (15.2) | 16 (19.3) | |
| Grade ≥3 CAR-T toxicity, no. (%) | ||||
| CRS | 11 (8.5) | 6 (13.0) | 5 (6.0) | .20* |
| ICANS | 22 (16.9) | 8 (17.4) | 13 (15.7) | .80 |
| DS at 1 mo, no. (%) | ||||
| DS 1-2 | 40 (30.8) | 6 (13.0) | 34 (41.0) | <.0001† |
| DS 3 | 31 (23.8) | 10 (21.7) | 21 (25.3) | |
| DS 4 | 46 (35.4) | 17 (37.0) | 28 (33.7) | |
| DS 5 | 13 (10.0) | 13 (28.3) | 0 |
Exclusion of n = 1 patient with nonrelapse death prior to 3-mo assessment (not evaluable for durability of response). P values are Wilcoxon Mann-Whitney (continuous) or χ2 (discrete, except *Fisher’s exact test and †χ2 for trend).
COO, cell of origin; CRS, cytokine release syndrome; GCB, germinal center B-cell; ICANS, immune effector cell-associated neurotoxicity syndrome; ULN, upper limit of normal.